DANIEL R. PASSERI - 30 Sep 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
30 Sep 2021
Net transactions value
-$461,534
Form type
4
Filing time
08 Oct 2021, 16:00:19 UTC
Previous filing
27 Sep 2021
Next filing
29 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise +75,000 +135% 130,377 30 Sep 2021 Direct F1
transaction CUE Common Stock Tax liability $461,534 -31,677 -24% $14.57 98,700 30 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Restricted Stock Units Options Exercise $0 -75,000 -50% $0.000000 75,000 30 Sep 2021 Common Stock 75,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3 One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022.